Latest Breaking News On - Adamis pharmaceuticals corporation nasdaq - Page 1 : comparemela.com

Adamis Pharmaceuticals (ADMP) Appoints Vickie Reed to its Board

Adamis Pharmaceuticals (ADMP) Appoints Vickie Reed to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoState of coloradoRichard williamsVickie reedUniversity of coloradoBristol myers squibbAmylin pharmaceuticals incAdamis pharmaceuticals corporation nasdaqZogenix incPrice waterhouseWall streetPharmaceuticals corporationAdamis boardSenior vice presidentChief accounting officer

Adamis Pharmaceuticals Announces Results of Tempol in

Tempol Reduced Lung Inflammation After High Dose Challenge.

Robert uhlAleksandrak drelichDennisj carloKent tsengCenters for diseaseCompany phaseAdamis pharmaceuticals corporationAdamis pharmaceuticalsAdamis pharmaceuticals corporation nasdaqUniversity of texas medical branchGalveston national laboratoryDepartment of microbiologyPharmaceuticals corporationTexas medical branchChien te kent tsengBi hung peng

Adamis Pharmaceuticals Corporation Issues Nationwide

SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of SYMJEPI.

United statesCraig stenlandRobert uhlDrug administrationAdamis pharmaceuticalsAdamis pharmaceuticals corporation nasdaqPharmaceuticals corporationPre filled single dose syringesWatch adverse event reportingNasdaq admpAdamis pharmaceuticals corporationAdamis pharmaceuticalsLlergic reaction

Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of SYMJEPI® (epinephrine) Injection for Potential Manufacturing Defect

SAN DIEGO, March 21, 2022 Adamis Pharmaceuticals Corporation is voluntarily recalling certain lots of SYMJEPI Injection 0.15 mg and 0.3 mg Pre-Filled Single-Dose Syringes to the. | March 21, 2022

United statesCraig stenlandRobert uhlAdamis pharmaceuticals corporationDrug administrationAdamis pharmaceuticalsAdamis pharmaceuticals corporation nasdaqGlobenewswire incPharmaceuticals corporationPre filled single dose syringesWatch adverse event reportingAdamis pharmaceuticals corporation stock exchangePress releaseO admp us00547w2089

Adamis Pharmaceuticals Provides Update on Clinical Study

DSMB met to evaluate interim clinical and safety data and clears Phase 2/3 study to continue.

New yorkUnited statesRobert uhlDennisj carloUs compounding incCompany phaseAdamis pharmaceuticals corporationAdamis pharmaceuticalsAdamis pharmaceuticals corporation nasdaqPharmaceuticals corporationData safety monitoring boardChief executive officerPrivate securities litigation reform actSouthern districtNasdaq admpAdamis pharmaceuticals corporation